Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.
Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma.
In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells.
Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines.
The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors.
Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 31, 25 | -0.53 Increased by +20.90% | -0.47 Decreased by -11.98% |
| Nov 13, 25 | -0.69 Increased by +89.06% | -0.55 Decreased by -25.45% |
| Aug 7, 25 | -0.56 Increased by +77.15% | -0.55 Decreased by -1.82% |
| May 6, 25 | -1.41 Decreased by -432.08% | -0.56 Decreased by -151.79% |
| Mar 20, 25 | -0.67 Decreased by -59.87% | -3.13 Increased by +78.59% |
| Nov 15, 24 | -6.31 Decreased by -2.73 K% | - |
| Aug 9, 24 | -2.45 Decreased by -483.40% | - |
| May 9, 24 | -0.27 Increased by +36.90% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | N/A Decreased by -100.00% | -14.47 M Decreased by -2.27 K% | - - |
| Sep 30, 25 | 0.00 Decreased by N/A% | -18.13 M Increased by +37.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -14.73 M Decreased by -31.51% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -14.11 M Decreased by -16.52% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 5.86 M Increased by +1.66 K% | -610.00 K Increased by +96.74% | Decreased by -10.42% Increased by +99.81% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -28.87 M Decreased by -93.43% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -11.20 M Increased by +40.08% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 333.00 K Decreased by -74.11% | -12.11 M Increased by +35.31% | Decreased by -3.64 K% Decreased by -149.82% |